Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1944 | Inhaled beclomethasone Wiki | 1.00 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D014777 | Virus Diseases NIH | 0.11 |
| D003141 | Communicable Diseases NIH | 0.07 |
| D007239 | Infection NIH | 0.05 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Severe SARS-CoV-2 disease is characterized by a progressive hypoxemic respiratory failure. Autopsies from these patients show severe endothelial damage with extensive vascular thrombosis, microangiopathy, and occlusion of alveolar capillaries and, finally, evidence of new vessel growth through intussusceptive angiogenesis. This research aims to study endothelial damage and angiogenesis biomarkers and its association with major cardiovascular events.
Description: Elevation of plasma Syndecan-1
Measure: Change from Baseline Syndecan-1 concentration at 10th day Time: 24 Hours, 10 DaysDescription: Elevation of plasma ANG-2
Measure: Change from Baseline ANG-2 concentration at 10th day Time: 24 Hours, 10 DaysDescription: Elevation of plasma FGF basic
Measure: Change from Baseline FGF basic concentration at 10th day Time: 24 Hours, 10 DaysDescription: Elevation of plasma HGF
Measure: Change from Baseline HGF concentration at 10th day Time: 24 Hours, 10 DaysDescription: Elevation of plasma IL-8
Measure: Change from Baseline IL-8 concentration at 10th day Time: 24 Hours, 10 DaysDescription: Elevation of plasma PDGF-BB
Measure: Change from Baseline PDGF-BB concentration at 10th day Time: 24 Hours, 10 DaysDescription: Elevation of plasma TIMP-1
Measure: Change from Baseline TIMP-1 concentration at 10th day Time: 24 Hours, 10 DaysDescription: Elevation of plasma TIMP-2
Measure: Change from Baseline TIMP-2 concentration at 10th day Time: 24 Hours, 10 DaysDescription: Elevation of plasma TNFα
Measure: Change from Baseline TNFα concentration at 10th day Time: 24 Hours, 10 DaysDescription: Elevation of plasma VEGF
Measure: Change from Baseline VEGF concentration at 10th day Time: 24 Hours, 10 DaysDescription: Elevation of plasma Thrombomodulin
Measure: Change from Baseline Thrombomodulin concentration at 10th day Time: 24 Hours, 10 DaysDescription: Acute coronary syndrome, myocardial injury, pulmonary embolism, and death.
Measure: Major cardiovascular events Time: 1 month, 3 months, 6 months 12 months.Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports